Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from XOMA Royalty Corporation ( (XOMA) ) is now available.
On April 27, 2026, XOMA Royalty Corporation entered into a merger agreement under which Flex Merger Sub, a wholly owned subsidiary of Ligand Pharmaceuticals, will merge with a newly formed Nevada entity, XOMA Royalty Holdings Corporation, created to implement a holding company reorganization under Nevada law. The transaction will result in HoldCo surviving as a wholly owned subsidiary of Ligand, with the structure designed to facilitate Ligand’s proposed acquisition of XOMA Royalty.
On May 16, 2026, the parties executed an amendment to the merger agreement that formally adds XOMA Royalty Holdings Corporation as a party to the deal, further aligning the holding company structure with the planned combination. XOMA Royalty also indicated it will file proxy materials with the SEC for stockholder approval of the acquisition, while highlighting regulatory, integration, market and legal risks that could affect completion and the anticipated benefits of the transaction for stakeholders.
The most recent analyst rating on (XOMA) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on XOMA Royalty Corporation stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
The score is driven primarily by improved recent profitability and free cash flow, tempered by balance-sheet leverage and historical/ongoing volatility. Technicals add support via a strong uptrend, while valuation is only moderate at ~20.9x earnings. Corporate events are a positive catalyst given the announced acquisition terms and potential CVR upside.
To see Spark’s full report on XOMA stock, click here.
More about XOMA Royalty Corporation
XOMA Royalty Corporation is a Nevada-based company that derives value from a portfolio of royalty and milestone interests, primarily linked to pharmaceutical and biotechnology products under development or commercialization. Its business model focuses on collecting and managing these royalty streams, positioning the company as a specialized player in the life sciences royalty financing market.
Average Trading Volume: 224,309
Technical Sentiment Signal: Buy
Current Market Cap: $523.6M
Find detailed analytics on XOMA stock on TipRanks’ Stock Analysis page.